Evaluating the long-term survival benefits of high intensity focused ultrasound ablation for hepatocellular carcinoma with portal vein tumor thrombus: a single center retrospective study
Aims To evaluate the long-term survival benefits of high intensity focused ultrasound (HIFU) ablation in patients with hepatocellular carcinoma (HCC) combined with portal vein tumor thrombus (PVTT).Methods The data of patients with HCC-PVTT treated with HIFU from January 2014 to December 2019 were r...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-12-01
|
| Series: | International Journal of Hyperthermia |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/02656736.2022.2122595 |
| _version_ | 1828413474778120192 |
|---|---|
| author | Xing Chen Yuhong Ma Jun Zhang Wei Yang Chengbing Jin Lifeng Ran Hui Zhu Jin Bai Kun Zhou |
| author_facet | Xing Chen Yuhong Ma Jun Zhang Wei Yang Chengbing Jin Lifeng Ran Hui Zhu Jin Bai Kun Zhou |
| author_sort | Xing Chen |
| collection | DOAJ |
| description | Aims To evaluate the long-term survival benefits of high intensity focused ultrasound (HIFU) ablation in patients with hepatocellular carcinoma (HCC) combined with portal vein tumor thrombus (PVTT).Methods The data of patients with HCC-PVTT treated with HIFU from January 2014 to December 2019 were retrospectively analyzed. All patients received HIFU ablation for both PVTT and liver tumor in one session. Perioperative adverse events (AEs) were recorded, and follow-up was performed postoperatively. The Kaplan–Meier method was used for survival analysis.Results Median follow-up was 13.75 ± 1.31 months. A total of 144 patients (male/female: 122/22, age: 54.15 ± 11.84 years old) were included in the study. A total of 267 liver tumors (tumor number: 1.87 ± 1.65, range 1–10) were treated with HIFU. The mean ± SD diameter of viable liver tumors was 100.98 ± 61.65 mm. The reported postoperative AEs of HIFU were skin edema (93.75%), local pain (69.44%) and fever (7.64%). There was no liver failure, gastrointestinal bleeding or perioperative death. The median overall survival (OS) time was 14 months, while the cumulative survival rates of 0.5, 1, 2 and 3 years were 79.0%, 58.6%, 33.3% and 5.9%, respectively. The median OS of PVTT types I, II and III was 22, 13 and 14 months, respectively, and the difference was not statistically significant (p > 0.05).Conclusion HIFU is a minimally invasive method for HCC-PVTT with fewer complications, which could prolong the OS. Patients with PVTT type III could benefit more from HIFU, compared to types I and II. |
| first_indexed | 2024-12-10T13:10:16Z |
| format | Article |
| id | doaj.art-f83294ec26e24d57bbbe5ae3bcbe78e9 |
| institution | Directory Open Access Journal |
| issn | 0265-6736 1464-5157 |
| language | English |
| last_indexed | 2024-12-10T13:10:16Z |
| publishDate | 2022-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | International Journal of Hyperthermia |
| spelling | doaj.art-f83294ec26e24d57bbbe5ae3bcbe78e92022-12-22T01:47:42ZengTaylor & Francis GroupInternational Journal of Hyperthermia0265-67361464-51572022-12-013911245125310.1080/02656736.2022.2122595Evaluating the long-term survival benefits of high intensity focused ultrasound ablation for hepatocellular carcinoma with portal vein tumor thrombus: a single center retrospective studyXing Chen0Yuhong Ma1Jun Zhang2Wei Yang3Chengbing Jin4Lifeng Ran5Hui Zhu6Jin Bai7Kun Zhou8State Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University, Chongqing, ChinaClinical Center for Tumor Therapy, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, ChinaClinical Center for Tumor Therapy, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, ChinaClinical Center for Tumor Therapy, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, ChinaClinical Center for Tumor Therapy, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, ChinaClinical Center for Tumor Therapy, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, ChinaClinical Center for Tumor Therapy, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, ChinaState Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University, Chongqing, ChinaClinical Center for Tumor Therapy, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, ChinaAims To evaluate the long-term survival benefits of high intensity focused ultrasound (HIFU) ablation in patients with hepatocellular carcinoma (HCC) combined with portal vein tumor thrombus (PVTT).Methods The data of patients with HCC-PVTT treated with HIFU from January 2014 to December 2019 were retrospectively analyzed. All patients received HIFU ablation for both PVTT and liver tumor in one session. Perioperative adverse events (AEs) were recorded, and follow-up was performed postoperatively. The Kaplan–Meier method was used for survival analysis.Results Median follow-up was 13.75 ± 1.31 months. A total of 144 patients (male/female: 122/22, age: 54.15 ± 11.84 years old) were included in the study. A total of 267 liver tumors (tumor number: 1.87 ± 1.65, range 1–10) were treated with HIFU. The mean ± SD diameter of viable liver tumors was 100.98 ± 61.65 mm. The reported postoperative AEs of HIFU were skin edema (93.75%), local pain (69.44%) and fever (7.64%). There was no liver failure, gastrointestinal bleeding or perioperative death. The median overall survival (OS) time was 14 months, while the cumulative survival rates of 0.5, 1, 2 and 3 years were 79.0%, 58.6%, 33.3% and 5.9%, respectively. The median OS of PVTT types I, II and III was 22, 13 and 14 months, respectively, and the difference was not statistically significant (p > 0.05).Conclusion HIFU is a minimally invasive method for HCC-PVTT with fewer complications, which could prolong the OS. Patients with PVTT type III could benefit more from HIFU, compared to types I and II.https://www.tandfonline.com/doi/10.1080/02656736.2022.2122595Hepatocellular carcinomaportal vein tumor thrombushigh intensity focused ultrasound ablationsurvival analysisthermal ablation |
| spellingShingle | Xing Chen Yuhong Ma Jun Zhang Wei Yang Chengbing Jin Lifeng Ran Hui Zhu Jin Bai Kun Zhou Evaluating the long-term survival benefits of high intensity focused ultrasound ablation for hepatocellular carcinoma with portal vein tumor thrombus: a single center retrospective study International Journal of Hyperthermia Hepatocellular carcinoma portal vein tumor thrombus high intensity focused ultrasound ablation survival analysis thermal ablation |
| title | Evaluating the long-term survival benefits of high intensity focused ultrasound ablation for hepatocellular carcinoma with portal vein tumor thrombus: a single center retrospective study |
| title_full | Evaluating the long-term survival benefits of high intensity focused ultrasound ablation for hepatocellular carcinoma with portal vein tumor thrombus: a single center retrospective study |
| title_fullStr | Evaluating the long-term survival benefits of high intensity focused ultrasound ablation for hepatocellular carcinoma with portal vein tumor thrombus: a single center retrospective study |
| title_full_unstemmed | Evaluating the long-term survival benefits of high intensity focused ultrasound ablation for hepatocellular carcinoma with portal vein tumor thrombus: a single center retrospective study |
| title_short | Evaluating the long-term survival benefits of high intensity focused ultrasound ablation for hepatocellular carcinoma with portal vein tumor thrombus: a single center retrospective study |
| title_sort | evaluating the long term survival benefits of high intensity focused ultrasound ablation for hepatocellular carcinoma with portal vein tumor thrombus a single center retrospective study |
| topic | Hepatocellular carcinoma portal vein tumor thrombus high intensity focused ultrasound ablation survival analysis thermal ablation |
| url | https://www.tandfonline.com/doi/10.1080/02656736.2022.2122595 |
| work_keys_str_mv | AT xingchen evaluatingthelongtermsurvivalbenefitsofhighintensityfocusedultrasoundablationforhepatocellularcarcinomawithportalveintumorthrombusasinglecenterretrospectivestudy AT yuhongma evaluatingthelongtermsurvivalbenefitsofhighintensityfocusedultrasoundablationforhepatocellularcarcinomawithportalveintumorthrombusasinglecenterretrospectivestudy AT junzhang evaluatingthelongtermsurvivalbenefitsofhighintensityfocusedultrasoundablationforhepatocellularcarcinomawithportalveintumorthrombusasinglecenterretrospectivestudy AT weiyang evaluatingthelongtermsurvivalbenefitsofhighintensityfocusedultrasoundablationforhepatocellularcarcinomawithportalveintumorthrombusasinglecenterretrospectivestudy AT chengbingjin evaluatingthelongtermsurvivalbenefitsofhighintensityfocusedultrasoundablationforhepatocellularcarcinomawithportalveintumorthrombusasinglecenterretrospectivestudy AT lifengran evaluatingthelongtermsurvivalbenefitsofhighintensityfocusedultrasoundablationforhepatocellularcarcinomawithportalveintumorthrombusasinglecenterretrospectivestudy AT huizhu evaluatingthelongtermsurvivalbenefitsofhighintensityfocusedultrasoundablationforhepatocellularcarcinomawithportalveintumorthrombusasinglecenterretrospectivestudy AT jinbai evaluatingthelongtermsurvivalbenefitsofhighintensityfocusedultrasoundablationforhepatocellularcarcinomawithportalveintumorthrombusasinglecenterretrospectivestudy AT kunzhou evaluatingthelongtermsurvivalbenefitsofhighintensityfocusedultrasoundablationforhepatocellularcarcinomawithportalveintumorthrombusasinglecenterretrospectivestudy |